| Literature DB >> 17222199 |
Anjli Kukreja1, Aisha Hutchinson, Amitabha Mazumder, David Vesole, Revathi Angitapalli, Sundar Jagannath, Owen A O'connor, Madhav V Dhodapkar.
Abstract
Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17222199 DOI： 10.1111/j.1365-2141.2006.06369.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998